| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Apellis Pharmaceuticals, Inc.
13D/A
APLS · 03753U106
|
0% |
5/14/2026
Event 5/14/2026
|
||||
|
Sage Therapeutics, Inc.
13D/A
SAGE · 78667J108
|
0% |
7/30/2025
Event 7/30/2025
|
||||
| Biogen Inc. | 0% | |||||
| Biogen MA Inc. | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.